Department of Otolaryngology-Head and Neck Surgery, University of Tsukuba, Tsukuba, Japan.
Department of Otolaryngology-Head and Neck Surgery, University of Tsukuba, Tsukuba, Japan.
Auris Nasus Larynx. 2023 Aug;50(4):601-606. doi: 10.1016/j.anl.2022.12.014. Epub 2023 Jan 3.
The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes.
The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (<0.3 mg/dl) and elevated (≥0.3 mg/dl) CRP groups according to the CRP level after the first cycle of cisplatin. The primary endpoint was progression-free survival (PFS).
A total of 74 patients were enrolled, of whom 36 (49%) showed elevated CRP levels after the first cycle of cisplatin. The 3-year PFS was 83.3% and 61.0% in the normal and elevated CRP groups, respectively, showing significant differences between the two groups.
Elevated CRP levels after the first cycle of cisplatin is an objective predictive marker for survival in patient with head and neck squamous cell carcinoma treated with CCRT.
已有研究报道，头颈部癌症患者治疗前 C 反应蛋白（CRP）水平与预后相关。然而，CRP 水平在治疗过程中的变化与预后之间的关系尚不清楚。本研究旨在探讨同期放化疗（CCRT）过程中 CRP 升高与生存结局之间的相关性。
回顾性分析了 2014 年 4 月至 2019 年 12 月在筑波大学医院和日本国立医院组织水户医疗中心接受 CCRT 治疗的口咽癌、下咽癌和喉癌患者的病历。根据顺铂治疗后第一周期的 CRP 水平，将患者分为正常（<0.3mg/dl）和升高（≥0.3mg/dl）CRP 组。主要终点是无进展生存期（PFS）。
共纳入 74 例患者，其中 36 例（49%）在顺铂治疗后第一周期 CRP 升高。正常 CRP 组和升高 CRP 组的 3 年 PFS 分别为 83.3%和 61.0%，两组间差异有统计学意义。
CCRT 治疗的头颈部鳞状细胞癌患者中，顺铂治疗后第一周期 CRP 升高是预测生存的客观指标。
